Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.

NCT02315768 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG: GA101
DRUG: Ibrutinib

Sponsor

University of California, San Diego

Collaborators

[object Object]